Meeting
2023 ASCO Genitourinary Cancers Symposium
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
Authors
Maha H. A. Hussain
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
Maha H. A. Hussain , Masha Kocherginsky , Parminder Singh , Zin Myint , Di Maria Jiang , Elizabeth Marie Wulff-Burchfield , Elad Sharon , Richard Piekarz , Joshua J Meeks , David James VanderWeele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
03854474
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 506)
DOI
10.1200/JCO.2023.41.6_suppl.506
Abstract #
506
Poster Bd #
K10
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183).
First Author: Joshua J. Meeks
Poster
2024 ASCO Annual Meeting
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
First Author: Maha H. A. Hussain
Poster
2023 ASCO Annual Meeting
HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.
First Author: Zhengfu Fan
Poster
2021 ASCO Annual Meeting
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
First Author: Benjamin Miron